• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

40.32 +1.37 (+3.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,527
Open 38.95
Bid (Size) 37.60 (100)
Ask (Size) 64.32 (200)
Prev. Close 38.95
Today's Range 38.95 - 40.75
52wk Range 6.710 - 43.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
January 07, 2026
This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+1.4%
+1.4%
1 Month
-1.1%
-1.1%
3 Month
+40.2%
+40.2%
6 Month
+157.8%
+157.8%
1 Year
+152.8%
+152.8%

More News

Read More
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
December 08, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 04, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
September 17, 2025
Via MarketBeat
News headline image
What's going on in today's session ↗
September 11, 2025
Via Chartmill
News headline image
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
September 11, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
September 11, 2025
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
September 11, 2025
Via Chartmill
News headline image
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
September 11, 2025
Via Benzinga
News headline image
Thursday's session: gap up and gap down stocks ↗
September 11, 2025
Via Chartmill
News headline image
Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
September 11, 2025
Via Investor's Business Daily
News headline image
Discover the top movers in Thursday's pre-market session. ↗
September 11, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
September 11, 2025
Via Benzinga
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 02, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Inc (NASDAQ:MAZE) Reports Narrower Q2 2025 Loss, Extends Cash Runway to 2027 ↗
August 12, 2025
Via Chartmill
News headline image
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 12, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
July 28, 2025
Via Benzinga
News headline image
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
July 23, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
July 16, 2025
Via Benzinga

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 40.32
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap